It is difficult to differentiate Pneumocystis pneumonia (PCP) from rituximab-induced interstitial lung disease (RILD) in lymphoma patients with diffuse pulmonary infiltrates who are receiving rituximab-containing chemotherapy. Using a clinical scoring system, we aim to differentiate PCP from RILD who are receiving rituximab-containing chemotherapy. We reviewed the medical records of lymphoma patients who had received rituximab-containing chemotherapy between 2012 and 2015 in a tertiary hospital. Among 613 lymphoma patients receiving rituximab-containing chemotherapy, 97 (16%) had diffuse pulmonary infiltrates. Of these, 16 (16%) with an alternative diagnosis and 22 (23%) with an indeterminate diagnosis were excluded. Finally, 21 (22%) patients were classified as having PCP and the remaining 38 (39%) as having RILD. Fever, short duration of symptoms (≤5 days), systemic inflammatory response syndrome (SIRS), and severe extent of disease on CT scan (>75%) were more common in patients with PCP than in those with RILD. Clinical scores were determined using the following system: SIRS = score 1, symptom duration ≤5 days = score 1, extent of disease on CT >75% = score 4. A score of ≥2 differentiated PCP from RILD with 91% sensitivity (95% CI, 70-99) and 71% specificity (95% CI, 54-84). A clinical scoring system based on presence of SIRS, short
Introduction
Rituximab is a chimeric anti-CD20 IgG1 monoclonal antibody that has been widely used as an immunotherapeutic agent, either alone or in combination, to treat various lymphoid malignancies, nonhematologic connective tissue disorders, and antineutrophil cytoplasmic antibodyassociated vasculitis. 1 Pulmonary complications have by far the highest reported odds ratio among the side-effects of rituximab. 2, 3 The most serious of these complications is a diffuse pulmonary infiltrate resulting from rituximabinduced lung disease (RILD). [4] [5] [6] The recent systematic review of reported cases showed that the incidence of RILD ranged from 3.7 to 10.0%. 7 Another major complication is Pneumocystis pneumonia (PCP), a cause of death in patients with non-Hodgkin lymphoma who are receiving chemotherapy. 8, 9 Furthermore, the risk of developing PCP is greater with chemotherapy that contains rituximab than with chemotherapy lacking this agent. 10 KAMEL et al. reported about 15% of lymphoma patients who treated with biweekly R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) developed PCP. 11 The recent meta-analysis including seven studies revealed that the incidence of PCP in lymphoma patients with rituximab-contained regimen were about 3% (28/942). 12 Our previous study also demonstrated that the incidence rate of PCP in lymphoma patients with R-CHOP was 2.1% (14/713). 8 Thus, it is important to differentiate PCP from RILD in lymphoma patients with diffuse pulmonary infiltrates who are receiving rituximab-containing chemotherapy.
However, it is difficult to differentiate PCP from RILD in patients with diffuse pulmonary infiltrates. Invasive diagnostic work-up, including analysis of bronchoalveolar lavage (BAL) fluid, often permits definite diagnosis, but it is not always feasible (for reasons of time) and without risk in critically ill patients. We have compared the clinical characteristics and outcomes in lymphoma patients with PCP and RILD and created a clinical scoring system to differentiate these two diseases.
Materials and methods

Study population
In a retrospective study, we reviewed lymphoma patients who had received rituximab-containing chemotherapy between January 2012 and May 2015 in a tertiary-care hospital with 2700 beds in Seoul, Republic of Korea. We reviewed adult patients (≥16 years) with radiologic findings of bilateral lung infiltration in the course of treatment for lymphoma; patients who had an alternative diagnosis for bilateral lung infiltration were excluded. PCP was diagnosed from (1) a positive test result in an immunohistochemical antibody assay for Pneumocystitis jirovecii in BAL fluid from patients with respiratory symptoms and (2) radiologic findings compatible with PCP. 13 Patients were classified as having RILD if (1) diffuse bilateral pulmonary infiltrates were seen on CT scan, (2) there was no evidence of other respiratory infection, and (3) if they showed clinical improvement without receiving any drug active against P. jirovecii. Patients with indeterminate diagnosis where PCP could not be excluded but the above criteria were not satisfied were left out of the final analysis; for example, those who received therapeutic doses of an anti-Pneumocystis regimen but were without a positive immunohistochemical antibody assay for P. jirovecii in BAL fluid. This study was approved by the institutional review board of the Asan Medical Center.
Data collection
Baseline clinical characteristics such as age, sex, underlying condition or illness, and performance status were investigated. Lymphoma-related factors such as type of pathology, Ann Arbor stage, International Prognostic Index (IPI) risk group, type of chemotherapy, and laboratory findings for serum lactate dehydrogenase (LDH) at the time of first administration of rituximab were included. We collected variables related to rituximab therapy, such as the number of cycles of rituximab-containing therapy before pulmonary complications of diffuse lung infiltration, duration of rituximab therapy, and whether or not rituximab was re-administered after diagnosis of PCP or RILD. We also investigated symptoms, signs, duration of symptoms before the medical visit, laboratory findings including C-reactive protein and procalcitonin, antibiotic use, PCP-and RILDrelated mortality, in-hospital mortality, and 30-day, 60-day, and 90-day mortality. 14 16, 17 Receiver operating characteristic (ROC) curve analysis was used to differentiate PCP from RILD. The Youden index was used to select optimum cut-off points on ROC curves (optimal balance between sensitivity and specificity). Diagnostic performance was expressed as sensitivity, specificity, and positive and negative likelihood ratios.
Results
Patient characteristics
During the approximately 4-year study period, 613 lymphoma patients received rituximab-containing chemotherapy, and 97 (16%) of these patients had diffuse lung infiltration in radiologic findings. Of the 97 patients, 16 were excluded because an alternative diagnosis was made. Of the remaining 81 patients, a further 22 with an indeterminate diagnosis of PCP or RILD were excluded (13 patients received anti-Pneumocystis therapy in the absence of a positive result in the immunohistochemical antibody assay for P. jirovecii; nine patients received anti-Pneumocystis therapy without bronchofibroscopy or BAL analysis). Finally, 59 patients were included in the analysis: 21 patients with PCP and 38 with RILD ( Fig. 1) . Table 1 shows a comparison of the baseline characteristics of patients with PCP and RILD. Patients with RILD were older than those with PCP (mean 63 vs. 54 years, P = .04). Diffuse large B-cell lymphoma was the most common pathologic type of lymphoma (85% of PCP cases and 87% of RILD). Ann Arbor stage and IPI risk groups were similar in PCP and RILD. A total of 17 (81%) patients with PCP and 38 (100%) with RILD were treated with a R-CHOP chemotherapy regimen.
Clinical characteristics and outcomes
PCP showed a nonsignificant trend toward earlier occurrence after initiation of rituximab-containing chemotherapy (median 3 cycles, interquartile range [IQR] 1-5 cycles) than RILD (median 4 cycles, IQR 2-6 cycles), (Table 2 , Fig. 2 ). Of the PCP patients, 17 (81%) were admitted via the emergency department; of the RILD patients, 21 (55%) came into hospital via an outpatient clinic and 12 (32%) via the emergency department.
Fever was more common in PCP (91%) than in RILD (40%, P < .001). Dyspnea, cough, and sputum were similar in the two groups. SIRS was more frequent in patients with PCP (91%) than in those with RILD (34%, P < .001). The median duration of symptoms before medical visit was 4 days for PCP (IQR, 1-7 days) and 7 days for RILD (IQR, 3-13 days); patients with PCP (76%) were more likely to have shorter symptom duration ≤5 days than those with RILD (36%, P < .001, Table 2 ). Laboratory findings at the time of PCP and RILD diagnosis were similar.
The characteristic CT findings in PCP and RILD are shown in Table 2 and Supplementary Table 1 . Groundglass opacity (GGO) was observed in all PCP cases and in 95% (36/38) of RILD. When CT scans were compared, disease extent was greater in PCP than in RILD (P < .001). Peribronchoalveolar distribution was more frequent in PCP (29%) than in RILD (5%, P = .01). The most common predominant CT patterns were diffuse GGO followed by patch GGO, multifocal airspace or alveolar, diffuse airspace or alveolar, and diffuse reticular pattern both in PCP and in RILD. There was no statistically significant difference in predominant CT patterns between PCP and RILD. Two distinct chest CT images between PCP (diffuse and symmetric GGO, >75% extent, without zonal predominance) and RILD (patchy fibrotic consolidations, <25% extent, with upper zonal predominance) were shown in Supplementary Figures 1 and 2 , respectively. In addition, two similar chest CT images between PCP and RILD were shown in Supplementary Figures 3 and 4 , respectively. Bronchofibroscopy was performed in all patients with PCP and in 16 (42%) with RILD. All patients with PCP were treated with trimethoprim-sulfamethoxazole (TMP-SMX) and nine patients with RILD received TMP-SMX for <5 days. The 30-day mortality was similar in the two groups, but 60-and 90-day mortalities were higher in PCP than in RILD (P = .05 and P = .02, respectively).
Clinical scoring system to differentiate PCP from RILD
We created a clinical prediction model using β-coefficients as a scoring scale in a logistic regression model to differentiate PCP from RILD. The following variables were scored to develop the clinical scoring model: duration of symptoms ≤5 days = 1, SIRS = 1, severe extent of disease on CT = 4 (Table 3) ; thus, the combination of these three parameters created possible scores between 0 and 6 ( Table 4) . Based on ROC curve analysis, a clinical score ≥2 had 91% sensitivity (95% CI, 70-99) and 71% specificity (95% CI, 54-84) in differentiating PCP from RILD.
Discussion
In the present study, diffuse lung infiltration developed in 16% of those lymphoma patients who were treated with rituximab-containing chemotherapy. This is consistent with previous reports of 5-18% pulmonary complications such as pneumonia or pneumonitis in patients undergoing this therapy. 3, [18] [19] [20] Among patients with diffuse bilateral infiltration, approximately 40% were diagnosed as having RILD and 20% as having PCP. However, it is important to differentiate PCP from RILD in relation to reuse of rituximab or unnecessary exposure to the toxicity of TMP-SMX treatment. Although invasive work-up including BAL analysis often allows definite diagnosis, the clinical prediction model that we describe to differentiate PCP from RILD not only provides guidance for decisions on invasive work-up but is also helpful in choosing an empirical antibiotic regimen before the results of diagnostic tests are available. We have found that a clinical scoring system based on SIRS, duration of symptoms, and extent of disease on CT scan appears to be useful in differentiating PCP from RILD with 91% sensitivity and 71% specificity. Studies comparing the clinical manifestations of PCP and RILD have been rare. Our previous study showed that 91% of lymphoma patients with PCP presented with fever 8 and a recent review of 37 patients with RILD found that fever was observed in two-thirds of the patients. 5 The present study clearly shows that fever was more common in patients with PCP (91%) than in those with RILD (40%). In addition, we found that acute and severe presentations were more common in patients with PCP (Table 2) . However, these clinical presentations overlapped so much between the groups that it was difficult to differentiate PCP from RILD by considering clinical symptoms and signs alone. It is worth noting that the median number of cycles of rituximab-containing chemotherapy for PCP and RILD were similar (three or four cycles) (Table 2, Figure 2) , which is consistent with previous studies. 5, 8, 10, 11, 19 We also investigated the median time from last rituximab infusion to onset of symptoms and found that this was also similar in the two groups: PCP, median 12 days; RILD, median 11 days (P = .30, Table 2 ). Interestingly, two patients with RILD developed symptoms on the day of rituximab infusion. However, all patients with PCP have at least 5 days of duration from last rituximab infusion to symptom onset (Table 2) . Thus, neither the number of the cycles of rituximab-containing chemotherapy nor the time from rituximab infusion to symptom onset can assist in differentiating PCP from RILD. Nevertheless, as suggested in previous studies. 5, 21 RILD should be considered as the top priority in differential diagnosis when pulmonary infiltration appears within a few days or on the day of rituximab infusion. CT findings in RILD have been analyzed in a systematic literature review. More than one focal alveolar pattern was observed in about half the patients with RILD 5 ; in contrast, diffuse GGO or diffuse interstitial infiltration was frequent in patients with PCP. 8, 9 However, there are limited data on comparisons of CT findings in PCP and RILD. In the present study, the predominant pattern in CT was diffuse or patchy GGO in both PCP and RILD. There are two notable radiologic findings in PCP and RILD. First, in PCP most patients (95%) show nonzonal predominance (Supplementary Fig. 1 ), whereas in RILD, zonal predominance is lower (24%) or upper (18%, Supplementary Fig. 2 ). Nevertheless, more than half the patients with RILD also show nonzonal predominance (Supplementary Table 1) ; thus the pattern is too overlapping to differentiate PCP from RILD. Second, the extent of disease: >75% of PCP patients had severe disease. On CT scan, only three (8%) patients with RILD had severe disease, whereas PCP showed a significant trend toward more severe disease (Table 2) . Taken together, the CT findings combined with the clinical characteristics provide a reliable model for differentiating the two diseases (Table 3) . On the basis of the different clinical manifestations and the CT findings, we created a clinical scoring system to guide clinical decision on further invasive work-up, such as BAL analysis. If there is an insidious pattern of symptom onset and no SIRS (clinical score = 0), physicians can adopt a 'wait and see' approach, with or without use of steroid therapy. If patients have short duration of symptoms with SIRS and severe extent of disease on CT (clinical score = 6), immediate invasive work-up and prompt anti-Pneumocystis therapy may be warranted. Moreover, we believe that this clinical model could be helpful when an invasive procedure such as BAL is impossible, a timely procedure is not feasible, or a laboratory test for diagnosis of PCP shows suboptimal sensitivity (e.g., BAL analysis after commencement of antiPneumocystis therapy).
In real clinical practice, many physicians give empirical anti-Pneumocystis therapy and corticosteroid in lymphoma patients with diffuse bilateral infiltrates who are receiving rituximab-containing chemotherapy without the documentation of the etiologic diagnosis causing the CXR abnormality. We have some concerns on this approach. First, it has been known that about 30% of patients with PCP do not response to TMP-SMX therapy so the salvage therapy such as clindamycin plus primaquine is recommended. [22] [23] [24] [25] So if we do not differentiate PCP from RILD, it is difficult to decide whether the salvage therapy against PCP is needed or not in a given patient. Second, without the confirmation of PCP versus RILD, the continuation of rituximab-containing chemotherapy or the commencement of secondary prophylaxis with TMP-SMX is difficult to be decided in the lymphoma patient who needs further chemotherapy. In this context, the differential diagnosis between PCP and RILD is important. However, the decision on invasive work-up such as bronchoscopy is difficult in some clinical situations. We thus believe that this clinical scoring system can be used in the emergency department before the decision on further invasive work-up to evaluate the neccesity of risk procedure and select an empirical antibiotic regimen before the results of diagnostic tests are available. In addition, some patients may present with mild symptoms and visit outpatient clinic. At that time, physicians can use this scoring system as a useful adjunct to decide further diagnostic plan.
Our study has some limitations. First, some may have concern that typical clinical presentations of PCP such as fever and respiratory symptoms are easily differentiated from those of RILD. However, there are only limited data directly comparing clinical presentations of PCP to those of RILD in lymphoma patients, although previous studies revealed that clinical presentations of patients with RILD overlapped substantially with those of patients with PCP. 4, 5, 8, 9 Indeed, our data showed that about one quarter of patients initially received empirical TMP-SMX therapy before BAL PCP results were available (Table 2 ). So we assume that it is occasionally difficult to differentiate patients with RILD from those with PCP in real clinical practice. In this context, our comparative analyses and the scoring system to differentiate those of RILD from those of PCP may give physicians important information for the management of lymphoma patients with diffuse bilateral infiltrates who are receiving rituximab-containing chemotherapy. However, since the scoring system was not validated, the robust application of the scoring system to clinical practice is limited. Second, some may argue that the RILD inclusion criteria could have included PCP patients who had false-negative PCP from BAL fluid without anti-Pneumocystis therapy as RILD because we did not use new diagnostic methods such as PCR and (1-3) β-D-glucan. However, PCR-based techniques not only have improved the diagnostic sensitivity of BAL fluid, but also raised the concern on Pneumocystis colonization. 26, 27 However, the duration of this colonization and the efficacy of treating colonization to prevent disease are unknown. 26 Therefore, some patients with RILD and Pneumocystis colonization based on PCR-based diagnostic test could be classified as those with RILD in this study. Although colonization can occasionally be detected using immunohistochemical staining of respiratory specimen, PCR-based diagnostic tests are needed to determine the colonization of Pneumocystis because of the low organism burden associated with colonization. So we assume that if the patient who had negative conventional PCP test such as immunohistochemistry or did not undergo bronchoscopy showed clinical improvement without anti-Pneumocystis therapy he/she might be considered as at least not having clinically significant PCP needing anti-Pneumocystis therapy, regardless of Pneumocystis colonization in his/her respiratory tract. In addition, (1-3) β-D-glucan test was not available in our study. This test has been suggested as serologic biomarker for invasive fungal infection including PCP. 28, 29 Further studies on the usefulness of clinical scoring system are needed in resource-rich areas where (1-3) β-D-glucan test is available. Third, because of the observational design of the study, BAL analysis was at the discretion of the attending physician and was not done in about 55% of RILD cases. Therefore, milder cases of pulmonary manifestation could be included in patients with RILD than in those with PCP. In addition, the patients who were classified as RILD had self-limiting respiratory viral infections because bronchoscopy was not performed in all patients with RLID. However, this reflects well that these patients with RILD improved in real clinical practice without anti-Pneumocystis therapy or invasive diagnostic procedures. Fourth, this study took place in a center where lymphoma patients receiving rituximab-containing chemotherapy did not routinely receive PCP prophylaxis. Thus, it is not known whether our findings can be extrapolated to breakthrough PCP in lymphoma patients receiving anti-Pneumocystis drugs. However, because breakthrough PCP may be uncommon in lymphoma patients receiving PCP prophylaxis, this kind of comparative study between PCP and RILD is logically difficult to perform. We therefore assume that application of our findings in an PCP prophylaxis setting should be cautious as these kinds of specific data will be unavailable.
In conclusion, a substantial proportion of pulmonary complications treated with rituximab-containing chemotherapy occur in patients with PCP or RILD. Our data suggest that use of a scoring system based on clinical (SIRS, duration of symptoms ≤5 days) and radiological (severe disease) values is helpful in differentiating PCP from RILD.
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